Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies

Mostrar otras versiones (1)

Patients with hematologic malignancies have both an increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and higher morbidity/mortality. They have lower seroconversion rates after vaccination, potentially leading to inferior coronavirus disease 2019 (COVID-19) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Chien, Kelly S., Peterson, Christine B., Young, Elliana, Chihara, Dai, Manasanch, Elizabet E., Ramdial, Jeremy L., Thompson, Philip A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Health Services and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896882/
https://www.ncbi.nlm.nih.gov/pubmed/36696472
http://dx.doi.org/10.1182/bloodadvances.2022008827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896882/
https://www.ncbi.nlm.nih.gov/pubmed/36696472
http://dx.doi.org/10.1182/bloodadvances.2022008827

Ejemplares similares